**Additional file 1**

C)

Supplementary Fig. 1 Proportion with EDSS progression at each year by ≥2 versus 0–1 active T2 lesions at 6 months.

(a) Placebo/delayed treatment group; (b) IFN β-1a 22 µg SC tiw group; (c) IFN β-1a 44 µg SC tiw group. p values indicate differences between patients with differing lesion loads at 6 months within the treatment group. No statistically significant differences were seen in the IFN β-1a 44 µg SC tiw group. Values were calculated with a logistic regression model with predictor (≥2 vs. 0–1 T2 lesions) as a fixed effect; number of relapses within previous 2 years, age, baseline EDSS score, and baseline burden of disease were independent variables, and p values were calculated for the predictive effect of T2 lesion subgroups. *$p<0.05$; **$p<0.01$.

EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; SC: subcutaneously; tiw: three times weekly.